Overview of Intrarenal Pressure (IRP)

Michelle Semins, MD, details the variability in intrarenal pressures, explaining that while a clear safe threshold is unknown, pressures over 30-40 might be dangerous; she lists factors influencing these pressures, like inflow/outflow and scope size, and mentions potential complications from prolonged high pressures, such as urosepsis.

EP: 1.Overview of the Incidence, Diagnosis, and Treatment of Urinary Stones

EP: 2.The Evolving Role of Ureteroscopy in the Treatment of Urinary Stones

Now Viewing

EP: 3.Overview of Intrarenal Pressure (IRP)

EP: 4.Potential Complications Seen in Patients With Elevated IRP

EP: 5.Strategies for Reducing Risk of Elevated IRP

EP: 6.Key Treatment and Outcome Data for Patients Undergoing Therapy with Assistance of Ureteral Access Sheaths (UASs)

EP: 7.Factors for Consideration When Employing UASs In Patients With Urinary Stones

EP: 8.Methods for Continuous IRP Monitoring in Patients With Urinary Stones

EP: 9.Future Perspectives in the Treatment of Patients With Urinary Stones

Related Videos

Related Content

Advertisement

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

December 23rd 2024

Published ASPIRE data show noninferior stone-free rate with SURE vs URS

Hannah Clarke

The SURE procedure also demonstrated significantly better outcomes on the study’s secondary end points of stone clearance and residual stone volume.

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.

Related Content

Advertisement

March 3rd 2025

FDA updates in urology: February 2025

Hannah Clarke

A recap of the FDA submissions and regulatory decisions in urology from February 2025.

February 17th 2022

Why kidney stones will become more prevalent over time

Urology Times staff

“The prevalence of kidney stones has increased over 80% over the last 30 years, and the epidemiology has changed such that it's beginning at a younger age now,” says Gregory Tasian, MD, MSc, MSCE.

February 5th 2025

FDA awards orphan drug, rare pediatric disease designations to ABO-101 for PH1

Hannah Clarke

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

September 9th 2021

Dr. Krambeck investigates efficacy of Trilogy and ShockPulse-SE lithotripters

Urology Times staff

“You have tradeoffs with every device that you use,” says Amy E. Krambeck, MD.

December 23rd 2024

Published ASPIRE data show noninferior stone-free rate with SURE vs URS

Hannah Clarke

The SURE procedure also demonstrated significantly better outcomes on the study’s secondary end points of stone clearance and residual stone volume.

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.